Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder TreatmentSARASOTA, FL, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that the U.S. Patent and Trademark Office (USPTO) issued an Issue Notification for our previously filed patent application (No. 17/954,864) titled “Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females.” The projected patent number is 12,239,614 and the issue date of such patent will be March 4, 2025.
Silo Pharma Advances Intellectual Property Portfolio with Provisional Patent Filing for PTSD TreatmentSARASOTA, FL, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the filing of a provisional patent application with the U.S. Patent and Trademark Office (USPTO). This application, focused on its lead asset SPC-15, highlights Silo’s commitment to advancing treatments for stress-induced psychiatric disorders, including post-traumatic stress disorder (PTSD).
Silo Pharma Awarded US Patent for Groundbreaking PTSD Treatment and Prepares for SPC-15 Clinical TrialSARASOTA, FL, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that the U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance for patent application 17/954,864 for “Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females.” Following receipt of the Notice of Allowance, Silo filed the final issue paperwork, paid the issue fees, and expects formal issuance of the patent in the next 90 days
Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic PainSARASOTA, FL, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” “we,” “us,” “our,” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today issued a letter to shareholders highlighting the Company’s progress and potential for its lead assets SPC-15 and SP-26 as treatments for mental health and chronic pain management, respectively. The letter, in its entirety, is reprinted below.
Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related DisordersDual-action approach combining 5-HT4R Agonist (SPC-15) and NMDAR antagonist demonstrates enhanced efficacy in preclinical study for managing severe conditions
Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine ImplantThe implant demonstrates stability and consistent drug release, supporting further analytical testing and development
Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesSARASOTA, FL, July 22, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 763,638 shares of common stock at a purchase price of $2.75 per share. In a concurrent private placement, the Company issued unregistered warrants to purchase up to 763,638 shares of common stock at an exercise price of $2.75 per share that are immediately exercisable upon issuance and will expire five years following the date of issuance.
Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesSARASOTA, FL, July 19, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has entered into definitive agreements for the purchase and sale of 763,638 shares of common stock at a purchase price of $2.75 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered warrants to purchase up to 763,638 shares of common stock at an exercise price of $2.75 per share that will be immediately exercisable upon issuance and will expire five years following the date of issuance. The closing of the offering is expected to occur on or about July 22, 2024, subject to the satisfaction of customary closing conditions.
Silo Pharma Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesSARASOTA, FL, June 06, 2024 (GLOBE NEWSWIRE) -- SARASOTA, FL, June 6, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 917,432 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $2.18 per share (or per common stock equivalent in lieu thereof). In a concurrent private placement, the Company issued unregistered warrants to purchase up to 917,432 shares of common stock at an exercise price of $2.06 per share that are immediately exercisable upon issuance and will expire five years following the date of issuance.
Silo Pharma Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesSARASOTA, FL, June 05, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has entered into definitive agreements for the purchase and sale of 917,432 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $2.18 per share (or per common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered warrants to purchase up to 917,432 shares of common stock at an exercise price of $2.06 per share that will be immediately exercisable upon issuance and will expire five years following the date of issuance. The closing of the offering is expected to occur on or about June 6, 2024, subject to the satisfaction of customary closing conditions.
Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse PreventionThe study has identified a potentially new drug formulation that could potentially extend the period of remission and prevent relapse in patients with depression.
Silo Pharma Announces Positive Results for Intranasal PTSD TreatmentIntranasal Delivery of SPC-15 shows rapid and effective drug exposure for PTSD Therapy
Silo Pharma Announces Positive Results in Alzheimer’s Disease StudyPreclinical study shows SPC-14’s effectiveness against LH (luteinizing hormone) stress, helplessness, and anxiety.
Silo Pharma’s SPU-21 Peptide Shows Positive Results Against Rheumatoid ArthritisHuman tissue study assessed SPU-21’s efficiency, optimization, and binding affinity
Silo Pharma Engages Clarivate for Intellectual Property and Patent ManagementClarivate will monitor, manage, and maintain Company’s expanding IP portfolio
Silo Pharma’s SPU-21 Treatment for Autoimmune Disease Awarded U.S. PatentNew patent expands Company’s intellectual property and technology rights portfolio
Silo Pharma Announces Participation on Webull Corporate Communications Service PlatformWebull’s investor community can now access the SILO profile for real-time data and investor communications
Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21Phase 2 of study will further investigate the peptides’ method, optimization, and binding affinity in human tissue
Silo Pharma’s SPC-15 Awarded U.S. Patent Protecting Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer’s DiseaseENGLEWOOD CLIFFS, NJ, May 09, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent 11,622,948 titled “Biomarkers for Efficacy of Prophylactic Treatments Against Stress-Induced Affective Disorders.” The new patent claims cover the use of biomarkers in determining the efficacy of the Company’s portfolio drug SPC-15, a targeted prophylactic treatment utilizing ketamine compositions, as a method of treatment for a stress-induced affective disorder or stress-induced psychopathology.
Silo Pharma to Present at Psychedelic Drug Development ConferenceENGLEWOOD CLIFFS, NJ, April 24, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that James Kuo, M.D., Vice President of R&D, will speak at the 3rd Annual Psychedelic Therapeutics and Drug Development Conference being held May 15-16, 2023, in person, at the Hilton San Francisco Airport Bayfront in Burlingame, CA.
Silo Pharma Announces Positive Results from IND-Enabling Study of SP-26 for FibromyalgiaENGLEWOOD CLIFFS, NJ, March 15, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has achieved positive results for its toxicology study of SP-26, its novel time-released, dosage-controlled formulation of ketamine. The study results evaluated the feasibility of using a rising dose design or maximum feasibility.
Silo Pharma Announces Filing of Patent for Treatment of Alzheimer’sPatent application covers use of novel homing peptides to reduce toxicity and advance payload of therapeutic
Silo Pharma Announces Expansion of Intellectual Property PortfolioSilo Receives Issuance of U.S. Patent Covering SPC-15 Method for Treatment and Prevention of Stress-Induced Affective Disorders
Silo Pharma Announces Stock Repurchase ProgramENGLEWOOD CLIFFS, NJ, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that its board of directors has authorized a share repurchase program to acquire up to $1,000,000 of the Company's common stock. The Company may purchase common stock in the open market, through privately negotiated transactions, or otherwise, in compliance with the rules of the United States Securities and Exchange Commission and other applicable legal requirements. The Company had approximately 3,138,797 million shares of common stock outstanding as of November 10, 2022, as reported in its Quarterly Report for the period ended September 30, 2022.
Silo Pharma Issues Letter to Shareholders Detailing Progress on Pipeline Assets Combining Traditional Therapeutics with Psychedelic MedicineENGLEWOOD CLIFFS, NJ, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today issued a letter to shareholders highlighting the Company’s progress and potential for its portfolio of novel, IP-protected technologies and assets developed in collaboration with world-class medical research partners. The letter, in its entirety, is reprinted below.
Silo Pharma Achieves New Milestone for SP-26 Therapeutic -Initiates IND Enabling Study of Topical Ketamine FormulationENGLEWOOD CLIFFS, NJ, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced initial dosing in its IND-enabling study of SP-26, its novel time-released, topical formulation of ketamine.
Silo Pharma to Discuss Mainstream Pharma and Psychedelics at Wonderland Miami ConferenceENGLEWOOD CLIFFS, NJ, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that James Kuo, M.D. M.B.A, Vice President of R&D, will speak as a panelist at Wonderland: Miami, the largest business gathering in the psychedelic medicine sector. Silo Pharma is a sponsor of the three-day conference being held November 3-5, 2022, in Miami, Florida.
Silo Pharma extends research pact for Alzheimer’s and Stress Induced Anxiety TherapeuticsSilo and Columbia University continue research on SPC-14 for Alzheimer’s and SPC-15 for Stress Induced Disorders
Silo Pharma Initiates Toxicity Study of its Proprietary Ketamine Formulation for Treatment of FibromyalgiaStudies of SP-26, the company’s proprietary, time-released ketamine show positive results in reducing neuropathic nerve pain
Silo Pharma to Present at the Dawson James Small Cap Growth Conference on October 12Presentation to feature Company’s novel therapeutic candidates under development in collaboration with leading academic institutions
Silo Pharma Announces Closing of $5.75 Million Public Offering of Common Stock, Nasdaq Listing, and Full Exercise of Underwriter’s Over-Allotment OptionENGLEWOOD CLIFFS, NJ, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced the closing of its underwritten public offering of 1,150,000 shares of its common stock, which included the full exercise of the underwriters' over-allotment option to purchase 150,000 additional shares of common stock, at a public offering price of $5.00 per share.
Silo Pharma Announces Positive Results from its Topically Administered Formulation of KetamineSilo shows reversal of allodynia and hyperalgesia using its selected formulation and partnered, patented delivery system
